Double-blind randomized phase II results comparing concurrent high-dose cisplatin chemorradiation (CRT) plus debio 1143 or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN): A GORTEC study
Jean Bourhis(University of Lausanne), Y. Tao, C. Even(Institut Gustave Roussy), P. Boisselier(Institut de Recherche en Cancérologie de Montpellier), Y. Pointreau(Centre Hospitalier Universitaire de Nantes), Xinghua Sun(L'Hôpital Nord Franche-Comté), C. Le Tourneau(Université de Versailles Saint-Quentin-en-Yvelines), Clément Sire(Centre National de la Recherche Scientifique), M. Alfonsi(Centre Hospitalier Universitaire de Nantes), Sergio Szyldergemajn(Debiopharm (Switzerland)), Philippa Crompton, J. Miroir(Centre Jean Perrin), Florian Clatot, J-P. Delord, L. Martin(Groupe Hospitalier du Havre), M-C. Kaminsky-Forrett, Alexandre Coutté, F. Rolland(Institut de Cancérologie de l'Ouest), S. Brienza
Cited by 4
Related Papers
Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)
|Head & Neck|2005|1.8k
Critical Impact of Radiotherapy Protocol Compliance and Quality in the Treatment of Advanced Head and Neck Cancer: Results From TROG 02.02
|Journal of Clinical Oncology|2010|806
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
|The Lancet Oncology|2021|618
Phase II Multicenter Study of the Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab in Combination With Platinum-Based Chemotherapy in Patients With Platinum-Refractory Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
|Journal of Clinical Oncology|2005|491
Induction Chemotherapy Followed by Either Chemoradiotherapy or Bioradiotherapy for Larynx Preservation: The TREMPLIN Randomized Phase II Study
|Journal of Clinical Oncology|2013|418